Antibiotice S.A.

ATB

ROATBIACNOR9

Pharmaceuticals

End-of-day quote Bucharest S.E. Other stock markets 06:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
3 ^RON	-0.99%		-3.23%	+115.05%

Jun. 06	Antibiotice S.A. announced that it expects to receive $108.96 million in funding	CI
May. 15	Antibiotice S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Antibiotice Provides Earnings Guidance for the Full Year of Fiscal 2014

February 24, 2014 at 07:15 am EST

Antibiotice provided earnings guidance for the full year of fiscal 2014. The company expects its net profit to rise 6.0% to RON 30.55 million ($9.3 million/EUR 6.8 million) in 2014. Revenue is expected to total RON 356.2 million this year with total costs reaching RON 319.3 million.

Latest news about Antibiotice S.A.

Antibiotice S.A. announced that it expects to receive $108.96 million in funding	Jun. 05	CI
Antibiotice S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Antibiotice S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Antibiotice S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-14	CI
Antibiotice S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Antibiotice S.A. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-11-10	CI
Antibiotice S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-15	CI
Antibiotice S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-27	CI
Antibiotice S.A. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-11-11	CI
Antibiotice S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	21-07-25	CI
Antibiotice S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-11	CI
Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-25	CI
Antibiotice S.A. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-11-11	CI
Antibiotice S.A. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-13	CI
Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2019	20-02-26	CI
Antibiotice S.A. Reports Earnings Results for the Nine Months Ended September 30, 2019	19-12-10	CI
Antibiotice S.A. Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-09	CI
Antibiotice S.A. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-14	CI
Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2018	19-02-28	CI
Antibiotice S.A. Reports Earnings Results for the Year Ended December 31, 2017	18-02-13	CI
Antibiotice lasi Announces Earnings Results for the Nine Months of 2017	17-11-14	CI
Antibiotice Announces Earnings Results for the First Half Ended June 2017	17-08-17	CI

Chart Antibiotice S.A.

Duration

Period

More charts

Company Profile

Antibiotice SA is a Romania-based company primarily active in the pharmaceutical industry. The Company manufactures drugs in five pharmaceutical forms: powder for injectable solutions and suspensions, capsules, tablets, suppositories and preparations. The Company's products are designed to treat a range of diseases, including infectious, dermatology, cardiovascular, digestive and musculoskeletal system related. The Company operates eight certified production lines. Its portfolio includes products for human and veterinary use, pharmaceutical ingredients and biological fertilizers. Additionally, the Company is engaged in the research and development activities.

Sector

Pharmaceuticals

Calendar

2024-09-22 - Détachement de for final dividend

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ANTIBIOTICE S.A.	+115.05%	442M
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+41.36%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.51%	247B
ROCHE HOLDING AG	+6.13%	230B
NOVARTIS AG	+18.53%	228B
AMGEN INC.	+14.86%	177B